Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapeutics source : Www.allogene.com save search
Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023
Published: 2023-04-25 (Crawled : 13:00) - allogene.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 0.0%
H: 9.68%
C: 4.28%
report therapeutics financial results
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
Published: 2023-04-20 (Crawled : 21:00) - allogene.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: -0.8%
H: 10.81%
C: 9.29%
therapeutics moore
Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences
Published: 2023-04-13 (Crawled : 13:00) - allogene.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 1.31%
H: 12.04%
C: 8.6%
therapeutics
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
Published: 2023-03-30 (Crawled : 13:00) - allogene.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 0.78%
H: 1.55%
C: -3.5%
report therapeutics
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
Published: 2023-03-02 (Crawled : 14:00) - allogene.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: -0.79%
H: 2.7%
C: -4.29%
therapeutics
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Published: 2023-02-28 (Crawled : 22:00) - allogene.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 6.14%
H: 5.93%
C: -5.93%
year therapeutics financial update results
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
Published: 2023-02-21 (Crawled : 14:00) - allogene.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: -2.08%
H: 0.72%
C: -5.25%
report therapeutics financial results
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
Published: 2023-01-25 (Crawled : 14:00) - allogene.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: -2.14%
H: 4.18%
C: 2.83%
lung research preclinical therapeutics potential cancer
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
Published: 2023-01-17 (Crawled : 22:00) - allogene.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 0.72%
H: 3.14%
C: -7.71%
therapeutics
Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Published: 2023-01-04 (Crawled : 14:00) - allogene.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 0.69%
H: 3.79%
C: 0.0%
conference therapeutics
Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer
Published: 2022-11-10 (Crawled : 14:20) - allogene.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 4.79%
H: 5.66%
C: 3.92%
immunotherapy meeting control therapeutics cancer
Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences
Published: 2022-11-09 (Crawled : 14:00) - allogene.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 0.22%
H: 0.45%
C: -2.34%
research therapeutics
Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase
Published: 2022-11-02 (Crawled : 21:00) - allogene.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: -7.47%
H: 4.2%
C: 1.17%
therapeutics financial results
Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products
Published: 2022-10-11 (Crawled : 13:00) - allogene.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: -0.09%
H: 5.05%
C: 1.19%
trial therapeutics therapy
Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial
Published: 2022-10-06 (Crawled : 21:00) - allogene.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: -0.64%
H: 12.12%
C: -4.87%
trial therapeutics phase 2
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
Published: 2022-08-03 (Crawled : 13:00) - allogene.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 2.08%
H: 9.4%
C: 6.66%
therapeutics
Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
Published: 2022-07-27 (Crawled : 13:00) - allogene.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 0.74%
H: 3.74%
C: 2.56%
report therapeutics results
Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors
Published: 2022-07-12 (Crawled : 13:20) - allogene.com
XNCR | $18.98 -0.47% -0.47% 470K
|
Health Technology
|
| O: 0.46%
H: 1.02%
C: 0.75%
SRPT | $116.59 -1.1% -1.12% 500K
|
Health Technology
|
| O: 0.07%
H: 0.39%
C: -1.33%
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 0.18%
H: 5.67%
C: 4.32%
therapeutics
Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma
Published: 2022-06-08 (Crawled : 13:00) - allogene.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 15.39%
H: 13.02%
C: 11.63%
allo-501 fda designation granted therapeutics therapy rmat
Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business Journal
Published: 2022-05-09 (Crawled : 13:00) - allogene.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: -1.97%
H: 0.0%
C: -18.28%
bay therapeutics
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.